Background Plasmodium falciparum, has developed resistance to many of the drugs in use.
The recommended treatment policy is now to use drug combinations. The atovaquone …

Abstract Background Resistance of Plasmodium falciparum to atovaquone in vitro and in
vivo has been associated to mutations in the parasite cytochrome b gene. Methods Cultures …

Atovaquone is the major active component of the new antimalarial drug Malarone.
Considerable evidence suggests that malaria parasites become resistant to atovaquone …

Drug resistance in malarial parasites has become a major obstacle in the control of the
disease. Strategies are urgently needed to control the development of resistance and to …

Background In vitro and in vivo resistance of Plasmodium falciparum to atovaquone or
atovaquone-proguanil hydrochloride combination has been associated to two point …

The molecular lesions which underlie the resistance of the malaria parasites to atovaquone,
a coenzyme Q analogue, were investigated. Resistant clones of Plasmodium berghei ANKA …

Atovaquone is a broad-spectrum antiparasitic agent active against malaria, Pneumocystis
carinii pneumonia, toxoplasmosis and babesiosis. When used as a single agent, resistance …

Suswam, E., Kyle, D., and Lang-Unnasch, N. 2001. Plasmodium falciparum: The effects of
atovaquone resistance on respiration. Experimental Parasitology98, 180–187. Atovaquone …

Background Atovaquone is part of the antimalarial drug combination atovaquone-proguanil
(Malarone®) and inhibits the cytochrome bc 1 complex of the electron transport chain in …

Atovaquone, a coenzyme Q analogue has been indicated to specifically target the
cytochrome bc 1 complex of the mitochondrial respiratory chain in the malarial parasite and …